Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Alcohol disorders

Drug relapse prophylaxis – how effective are the approved substances?

    • General Internal Medicine
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • RX
    • Studies
  • 2 minute read

Purpose: To provide a cost-benefit assessment of medications used in relapse prevention of alcohol disorders.

Background: Medications for relapse prevention of alcohol disorders in outpatient treatment settings are generally still underused, despite the fact that alcohol disorders are associated with significant secondary problems and increased mortality rates.

Patients and methodology: This American meta-analysis included randomized controlled trials (RCTs) published between January 1970 and March 2014. Using a systematic search of several medical databases, e.g. PubMed, EMBASE, Cochrane Library, etc., RCTs were collected that had lasted at least twelve weeks and met certain minimum methodological standards.

Results: There were 122 RCTs and one cohort study included in the meta-analysis (total of 22,803 patients). Most studies had examined acamprosate (27 studies, n=7519) and/or naltrexone (53 studies, n=9140). Regarding prevention of relapse, a Number Needed to Treat (NNT) of 12 was found for acamprosate, and an NNT of 20 was found for (oral) naltrexone. For prevention of severe drinking events, naltrexone achieved an NNT of 12. Regarding relapse prevention, there were no differences between acamprosate and naltrexone. The intramuscular depot form of naltrexone was not associated with relapse prevention, but a significant reduction in heavy drinking events was found. Moderate evidence was found for nalmefene (significant reduction in drinking days/month and significant reduction in drinking amount/day) and topiramate (significant reduction in heavy drinking events and drinking amount/day).

Authors’ conclusions: Acamprosate and naltrexone are associated with significant relapse prevention. When these two drugs are directly compared in terms of effectiveness, no statistical differences are seen. Factors such as potential side effects, availability, and frequency of use help guide decisions about which medication to use.

Comment: This is a methodologically high-quality and important paper by Jonas and colleagues, as the topic is also of very high clinical importance in Switzerland. Unfortunately, there is a large treatment gap for patients with alcohol dependence, i.e. the majority of those affected do not even receive adequate addiction medical treatment in the first place. The reasons for this are manifold: shame, stigmatization and faulty understanding of the disease among patients (but also among practitioners). Often, both parties are unaware that multiple effective pharmacologic treatment options are available. On a positive note, four drugs have so far been approved in Switzerland for the indication of alcohol relapse prophylaxis: Disulfiram, naltrexone, nalmefene and acamprosate. The drugs have pharmacodynamically different targets, so that on the one hand combination possibilities exist, but also with regard to patient wishes and previous experience a differentiated therapy indication is possible (e.g. support of complete abstinence by disulfiram and/or acamprosate or drinking quantity reduction by nalmefene or naltrexone). Primarily, the drugs approved in Switzerland should always be used.

 

InFo NEUROLOGY & PSYCHIATRY 2016; 14(3): 33.

Autoren
  • PD Dr. med. Jochen Mutschler
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Addiction
  • Alcohol
Previous Article
  • Parents critical of vaccination

How does the attending physician react correctly?

  • Education
  • General Internal Medicine
  • Infectiology
  • Pediatrics
  • Prevention and health care
  • RX
View Post
Next Article
  • Allergology in the form of a story

The fisherman who became allergic to everything

  • Allergology and clinical immunology
  • Dermatology and venereology
  • Education
  • RX
View Post
You May Also Like
View Post
  • 15 min
  • Diabetes mellitus

Treatment of comorbidities in older people

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • RX
View Post
  • 12 min
  • Liver steatosis with metabolic dysfunction

New nomenclature for non-alcoholic fatty liver disease

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 4 min
  • Type 2 diabetes: PAD and diabetic foot syndrome

Prevention is better than cure – don’t miss the risk foot

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Prevention and health care
    • RX
View Post
  • 2 min
  • Prostate cancer

High-resolution ultrasound could diagnose prostate cancer faster

    • Congress Reports
    • Oncology
    • RX
    • Studies
    • Urology
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 8 min
  • Psychooncology

Communication as the key to therapy adherence

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • RX
View Post
  • 16 min
  • Blastic plasmacytoid dendritic cell neoplasia

Rare malignancy from a dermatological perspective

    • CME continuing education
    • Dermatology and venereology
    • Genetics
    • Hematology
    • Oncology
    • RX
View Post
  • 4 min
  • From symptom to diagnosis

Lung carcinoma – Pancoast tumor

    • Cases
    • Education
    • Oncology
    • Pneumology
    • Radiology
    • RX
    • Surgery
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Treatment of comorbidities in older people
  • 2
    New nomenclature for non-alcoholic fatty liver disease
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Communication as the key to therapy adherence
  • 5
    Patience, knowledge and persistence in therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.